Trials / Active Not Recruiting
Active Not RecruitingNCT02839291
Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 148 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Besancon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the current medical practice and its influence on health-related quality of life, in patients who are treated with injectable bone antiresorptive drugs (biphosphonates or denosumab) for at least one year.
Detailed description
This protocol will evaluate the pursuit of injectable bone antiresorptive treatments or their switch to oral biphosphonates, or treatment stop, in the contexte of medical practice. The primary end-point is the health-related quality of life (QoL). Secondary endpoints are safety, overall survial, the impact of toxicities of the treatment on QoL, and the description of supportive care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | quality of life questionaries | |
| DRUG | intravenous or oral bone antiresorptive treatments |
Timeline
- Start date
- 2016-06-14
- Primary completion
- 2024-02-05
- Completion
- 2025-01-31
- First posted
- 2016-07-20
- Last updated
- 2024-12-27
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02839291. Inclusion in this directory is not an endorsement.